Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and (β12-β13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 1, 2009, Pages 45-53

  Swingle, Mark R ^a   Amable, Lauren ^a   Lawhorn, Brian G ^b   Buck, Suzanne B ^b   Burke, Christopher P ^b   Ratti, Pukar ^a   Fischer, Kimberly L ^a   Boger, Dale L ^b   Honkanen, Richard E ^a,c  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c MSB 2362 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 OXO 5,6 DIHYDRO 2H PYRAN 6 YL] 3,4,6,13 TETRAHYDROXY 3 METHYL 1,7,9,11 TRIDECATETRAENE 3,4 CYCLOPHOSPHATE; 1,5,8,11,18 PENTAHYDROXY 8 METHYLOCTADECA 6,12,14,16 TETRAEN 9 YL DIHYDROGEN PHOSPHATE; 11 DESHYDROXYCYTOSTATIN; 11 METHYL 2,4,6 DODECATRIENE 1,8,10,11 TETRAOL 10 PHOSPHATE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; CYSTEINE; DEPHOSPHOCYTOSTATIN; DEPHOSPHOFOSTRIECIN; EPI CYTOSTATIN; FOSTRIECIN; HEXESTROL DIPHOSPHATE; LACTONE; PHOSPHATASE; SERINE THREONINE PROTEIN PHOSPHATASE 1; SERINE THREONINE PROTEIN PHOSPHATASE 1 CATALYTIC SUBUNIT; SERINE THREONINE PROTEIN PHOSPHATASE 2A CATALYTIC SUBUNIT; SERINE THREONINE PROTEIN PHOSPHATASE 5 CATALYTIC SUBUNIT; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

ALKENES; AMINO ACID SEQUENCE; ANIMALS; CATALYTIC DOMAIN; CATTLE; ENZYME INHIBITORS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTANT CHIMERIC PROTEINS; NUCLEAR PROTEINS; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORIC ACID ESTERS; POLYENES; PROTEIN BINDING; PROTEIN PHOSPHATASE 1; PROTEIN PHOSPHATASE 2; PROTEIN STRUCTURE, TERTIARY; PYRONES; RABBITS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349312573     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.155630     Document Type: Article

References (40)

1. Bialy L and Waldmann H (2004) Total synthesis and biological evaluation of the protein phosphatase 2A inhibitor cytostatin and analogues. Chemistry 10:2759-2780.
2. Boger DL, Ichikawa S, and Zhong W (2001) Total synthesis of fostriecin (CI-920). J Am Chem Soc 123:4161-4167.
3. Buck SB, Hardouin C, Ichikawa S, Soenen DR, Gauss CM, Hwang I, Swingle MR, Bonness KM, Honkanen RE, and Boger DL (2003) Fundamental role of the fostriecin unsaturated lactone and implications for selective protein phosphatase inhibition. J Am Chem Soc 125:15694-15695. (Pubitemid 37553657)
4. Chavez DE and Jacobsen EN (2001) Total synthesis of fostriecin (CI-920). Angew Chem Int Ed Engl 40:3667-3670.
5. Chen HM, Liu BF, Huang HL, Hwang SF, and Ho SY (2007) SODOCK: swarm optimization for highly flexible protein-ligand docking. J Comput Chem 28:612-623.
6. Cho US and Xu W (2007) Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature 445:53-57. (Pubitemid 46067298)
7. Colby DA and Chamberlin AR (2006) Pharmacophore identification: the case of the Ser/Thr protein phosphatase inhibitors. Mini Rev Med Chem 6:657-665.
8. de Jong RS, de Vries EG, and Mulder NH (1997) Fostriecin: a review of the preclinical data. Anticancer Drugs 8:413-418.
9. Esumi T, Okamoto N, and Hatakeyama S (2002) Versatile enantiocontrolled synthesis of (+)-fostriecin. Chem Commun (Camb) 24:3042-3043.
10. Evans DR and Simon JA (2001) The predicted beta12-beta13 loop is important for inhibition of PP2Acalpha by the antitumor drug fostriecin. FEBS Lett 498:110-115.
11. Gasteiger J and Marsili M (1980) Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. Tetrahedron 36:3219-3228.
12. Goldberg J, Huang HB, Kwon YG, Greengard P, Nairn AC, and Kuriyan J (1995) Three-dimensional structure of the catalytic subunit of protein serine/threonine phosphatase-1. Nature 376:745-753.
13. Hassinen T and Peräkylä M (2001) New energy terms for reduced protein models implemented in an off-lattice force field. J Comput Chem 22:1229-1242.
14. Honkanen RE (2005) Serine/threonine protein phosphatase inhibitors with anti-tumor activity. Handbk Exp Pharm 167:295-317.
15. Honkanen RE, Zwiller J, Moore RE, Daily SL, Khatra BS, Dukelow M, and Boynton AL (1990) Characterization of microcystin-LR, a potent inhibitor of type 1 and type 2A protein phosphatases. J Biol Chem 265:19401-19404. (Pubitemid 120013875)
16. Jung WH, Guyenne S, Riesco-Fagundo C, Mancuso J, Nakamura S, and Curran DP (2008) Confirmation of the stereostructure of (+)-cytostatin by fluorous mixture synthesis of four candidate stereoisomers. Angew Chem Int Ed Engl 47:1130-1133. (Pubitemid 351204419)
17. Kawada M, Amemiya M, Ishizuka M, and Takeuchi T (1999) Differential induction of apoptosis in B16 melanoma and EL-4 lymphoma cells by cytostatin and bactobolin. Jpn J Cancer Res 90:219-225. (Pubitemid 29112323)
18. Kawada M, Kawatsu M, Masuda T, Ohba S, Amemiya M, Kohama T, Ishizuka M, and Takeuchi T (2003) Specific inhibitors of protein phosphatase 2A inhibit tumor metastasis through augmentation of natural killer cells. Int Immunopharmacol 3:179-188. (Pubitemid 36183377)
19. Kennedy J and Eberhart RC (1995) Particle swarm optimization, in Proceedings of IEEE International Conference on Neural Networks, (Perth, WA, Australia), Vol.4, pp 1942-1948. IEEE Service Center, Piscataway, NJ.
20. Lawhorn BG, Boga SB, Wolkenberg SE, Colby DA, Gauss CM, Swingle MR, Amable L, Honkanen RE, and Boger DL (2006) Total synthesis and evaluation of cytostatin, its C10-C11 diastereomers, and additional key analogues: impact on PP2A inhibition. J Am Chem Soc 128:16720-16732. (Pubitemid 46032751)
21. Lê LH, Erlichman C, Pillon L, Thiessen JJ, Day A, Wainman N, Eisenhauer EA, and Moore MJ (2004) Phase I and pharmacokinetic study of fostriecin given as an intravenous bolus daily for five consecutive days. Invest New Drugs 22:159-167. (Pubitemid 38270471)
22. Leopold WR, Shillis JL, Mertus AE, Nelson JM, Roberts BJ, and Jackson RC (1984) Anticancer activity of the structurally novel antibiotic Cl-920 and its analogues. Cancer Res 44:1928-1932.
23. Lewy DS, Gauss CM, Soenen DR, and Boger DL (2002) Fostriecin: chemistry and biology. Curr Med Chem 9:2005-2032.
24. Maki K, Motoki R, Fujii K, Kanai M, Kobayashi T, Tamura S, and Shibasaki M (2005) Catalyst-controlled asymmetric synthesis of fostriecin and 8-epi-fostriecin. J Am Chem Soc 127:17111-17117. (Pubitemid 41772872)
25. Masuda T, Watanabe S, Amemiya M, Ishizuka M, and Takeuchi T (1995) Inhibitory effect of cytostatin on spontaneous lung metastases of B16-BL6 melanoma cells. J Antibiot (Tokyo) 48:528-529.
26. Miyashita K, Ikejiri M, Kawasaki H, Maemura S, and Imanishi T (2003) Total synthesis of an antitumor antibiotic, fostriecin (CI-920). J Am Chem Soc 125: 8238-8243. (Pubitemid 36828587)
27. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, and Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639-1662. (Pubitemid 128590223)
28. Reddy YK and Falck JR (2002) Asymmetric total synthesis of (+)-fostriecin. Org Lett 4:969-971.
29. Ruvinsky AM and Kozintsev AV (2005) New and fast statistical- thermodynamic method for computation of protein-ligand binding entropy substantially improves docking accuracy. J Comput Chem 26:1089-1095.
30. Stouten PFW, Frömmel C, Nakamura H, and Sander C (1993) An effective solvation term based on atomic occupancies for use in protein simulations. Mol Simulat 10:97-120.
31. Susick RL Jr, Hawkins KL, and Pegg DG (1990) Preclinical toxicological evaluation of fostriecin, a novel anticancer antibiotic, in rats. Fundam Appl Toxicol 15:258-269.
32. Swingle M, Ni L, and Honkanen RE (2007) Small-molecule inhibitors of Ser/Thr protein phosphatases: specificity, use and common forms of abuse. Methods Mol Biol 365:23-38.
33. Swingle MR, Honkanen RE, and Ciszak EM (2004) Structural basis for the catalytic activity of human serine/threonine protein phosphatase-5. J Biol Chem 279: 33992-33999. (Pubitemid 39063050)
34. Trost BM, Frederiksen MU, Papillon JP, Harrington PE, Shin S, and Shireman BT (2005) Dinuclear asymmetric Zn aldol additions: formal asymmetric synthesis of fostriecin. J Am Chem Soc 127:3666-3667. (Pubitemid 40411385)
35. Usui T, Marriott G, Inagaki M, Swarup G, and Osada H (1999) Protein phosphatase 2A inhibitors, phoslactomycins. Effects on the cytoskeleton in NIH/3T3 cells. J Biochem 125:960-965. (Pubitemid 29253567)
36. Walsh AH, Cheng A, and Honkanen RE (1997) Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A. FEBS Lett 416:230-234. (Pubitemid 27475370)
37. Weiner SJ, Kollman PA, Case DA, Singh UH, Ghio C, Alagona G, Profeta S, and Weiner P (1984) A new force field for molecular mechanical simulation of nucleic acids and proteins. J Am Chem Soc 106:765-784. (Pubitemid 14548426)
38. Xing Y, Xu Y, Chen Y, Jeffrey PD, Chao Y, Lin Z, Li Z, Strack S, Stock JB, and Shi Y (2006) Structure of protein phosphatase 2A core enzyme bound to tumorinducing toxins. Cell 127:341-353. (Pubitemid 44572378)
39. Zhang J, Zhang Z, Brew K, and Lee EY (1996) Mutational analysis of the catalytic subunit of muscle protein phosphatase-1. Biochemistry 35:6276-6282. (Pubitemid 26164057)
40. Zhang Z, Zhao S, Long F, Zhang L, Bai G, Shima H, Nagao M, and Lee EY (1994) A mutant of protein phosphatase-1 that exhibits altered toxin sensitivity. J Biol Chem 269:16997-17000. (Pubitemid 24204012)